Colonic neoplasms
Conditions
Interventions
Lidocaine injection group: A mixture of sodium alginate and 1% lidocaine at a ratio of 1:1 is used as the local injection solution for ESD.
Control group: A mixture of sodium alginate and saline at a
Sponsors
Takashi Kanesaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients scheduled to undergo ESD for colonic neoplasms (2) Patients who are at least 18 years old at the time of enrollment (3) Patients with a performance status (PS) of 0-2 according to ECOG criteria (4) Patients who have given written consent to participate in the study.
Exclusion criteria
Exclusion criteria: (1) Patients with hypersensitivity to lidocaine (2) Patients with serious comorbidities (liver cirrhosis, renal failure, heart failure, hematological disease, etc.) (3) Pregnant patients (4) Patients who have already been enrolled in the study (5) Patients who are judged to be inappropriate as research subjects by the principal investigator or subinvestigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Procedure time | — |
Secondary
| Measure | Time frame |
|---|---|
| Peristalsis that interferes with ESD procedure, antispasmodic drug usage, en bloc resection rate, R0 resection rate, operator satisfaction, adverse events | — |
Contacts
Public ContactUeda Tomoya
Department of gastrointesitinal oncology, Osaka International Cancer Institute
Outcome results
None listed